Clinical Significance of Platelet Reactivity on Clopidogrel During Off-pump Coronary Artery Bypass
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Objective: To evaluate the early and late prognoses of patients according to platelet
reactivity after clopidogrel administration and determine whether the measurement of platelet
inhibition predicted 1-year clinical outcomes after off-pump coronary bypass (OPCAB) Study
design
- Prospective, observational, single-center study
- Subjects with OPCAB surgery who meet all inclusion and exclusion criteria will be
enrolled.
- Platelet reactivity after 7-days clopidogrel treatment from the day of surgery will be
measured by VerifyNow system.
- Dual antiplatelet therapy including aspirin and clopidogrel will be administered for 1
year after surgery and subjects will be followed-up for 1 year about primary endpoint.
- Cutoff value of P2Y12 reactivity units (PRUs) for primary endpoint will be assessed and
the cohort will be divided by the PRU cutoff value (low/high platelet reactivity
groups).
- The primary and secondary endpoints will be compared between two groups